FLSM
XLO icon

Frazier Life Sciences Management’s Xilio Therapeutics XLO Stock Holding History

Frazier Life Sciences Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.05M Hold
422,505
– – 0.09% 40
2026
Q1 		$3.55M Sell
422,505
-2
-0% -$16 0.09% 38
2025
Q4 		$3.79M Buy
+422,507
New +$4.44M 0.1% 39

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Frazier Life Sciences Management's XLO Position: Q2 2026 in Review

Frazier Life Sciences Management held its Xilio Therapeutics (XLO) position steady in Q2 2026 at 422,505 shares worth $4.05M. The position accounts for 0.09% of the portfolio, ranked #40.

Frazier Life Sciences Management first reported a position in XLO in Q4 2025 and has held it in 3 quarters since. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Frazier Life Sciences Management held 422,505 shares of Xilio Therapeutics worth $4.05M as of Q2 2026.
  • Frazier Life Sciences Management left its Xilio Therapeutics share count unchanged in Q2 2026.
  • Xilio Therapeutics made up 0.09% of Frazier Life Sciences Management's portfolio in Q2 2026, its #40 holding.
  • Frazier Life Sciences Management first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.